Agostinetto, E.; Montemurro, F.; Puglisi, F.; Criscitiello, C.; Bianchini, G.; Del Mastro, L.; Introna, M.; Tondini, C.; Santoro, A.; Zambelli, A.
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers 2022, 14, 2136.
https://doi.org/10.3390/cancers14092136
AMA Style
Agostinetto E, Montemurro F, Puglisi F, Criscitiello C, Bianchini G, Del Mastro L, Introna M, Tondini C, Santoro A, Zambelli A.
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers. 2022; 14(9):2136.
https://doi.org/10.3390/cancers14092136
Chicago/Turabian Style
Agostinetto, Elisa, Filippo Montemurro, Fabio Puglisi, Carmen Criscitiello, Giampaolo Bianchini, Lucia Del Mastro, Martino Introna, Carlo Tondini, Armando Santoro, and Alberto Zambelli.
2022. "Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives" Cancers 14, no. 9: 2136.
https://doi.org/10.3390/cancers14092136
APA Style
Agostinetto, E., Montemurro, F., Puglisi, F., Criscitiello, C., Bianchini, G., Del Mastro, L., Introna, M., Tondini, C., Santoro, A., & Zambelli, A.
(2022). Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers, 14(9), 2136.
https://doi.org/10.3390/cancers14092136
